Truist Securities Reiterates Hold on OrthoPediatrics, Raises Price Target to $34
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Hold rating on OrthoPediatrics and raised the price target from $30 to $34.
September 13, 2024 | 2:57 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Truist Securities has reiterated its Hold rating on OrthoPediatrics and increased the price target from $30 to $34, indicating a positive outlook.
The increase in the price target from $30 to $34 by Truist Securities suggests a positive outlook for OrthoPediatrics, which could lead to a short-term increase in stock price. However, the Hold rating indicates that the stock may not outperform the market significantly.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100